Methods: Aptamers were incubated with serum specimens and then electrophoresed on polyacrylamide gel (PAGE) and stained with GelRed. The gray value of the free aptamer band in each specimen was measured. The gray ratio of each specimen to the aptamer control was calculated. A mathematical diagnostic model was created with multivariate logistic regression analysis of gray indicators. The area under the receiver operating characteristic curve (AUC) and diagnostic performance were used to evaluate the diagnostic value of aptamers for PHC. Results: Twelve aptamers were evaluated in 72 cases of PHC and 108 cases of non-PHC (the cases of cirrhosis, hepatitis
B and normal controls were all 36). The Pembrolizumab research buy free bands of aptamer incubated with PHC specimens were usually weaker than that of non-PHC specimens, and the results of gray measurement were accorded with them. The diagnostic value of gray ratio and diagnostic model were showed in the table 1 below. This is firstly reported that aptamers against PHC serum applied in the study of diagnosis of PHC, and also PAGE combined gray analysis was firstly introduced to evaluate the diagnostic value of the aptamers. Conclusion: The Buparlisib ic50 aptamers against primary hepatic carcinoma serum are valuable in the diagnosis of primary hepatic carcinoma. Key Word(s): 1. Aptamer; 2. Serum; 3. Hepatoma; 4. Diagnosis; Aptamer Gray ratio Mathematical model AUC Sensitivity (%) Specificity MCE (%) Accuracy (%) AUC Sensitivity (%) Specificity (%) Accuracy (%) AP-HCS-9-10 0.881 76.4 83.3 80.6 0.913 86.1 86.1 86.1 AP-HCS-9-26 0.749 56.9 81.5 71.7 0.845 73.6 77.8 76.1 AP-HCS-9-31 0.768 66.7 77.8 73.3 0.853 65.1 85.5 78.3 AP-HCS-9-74 0.885 72.2 88.9 82.2 0.949 88.9 89.8 89.4 AP-HCS-9-89 0.688 43.1 80.6 65.6 0.931 81.9 90.7 87.2 AP-HCS-9-90 0.893 85.2 84.7 84.4 0.965 90.7 90.3 90.6 AP-HCS-9-132 0.862 75.0 83.3 80.0 0.918 76.4 90.7 85.0
AP-HCS-11-3 0.816 63.9 88.0 78.3 0.939 83.3 86.1 85.0 AP-HCS-11-4 0.859 72.2 85.2 80.0 0.894 79.2 80.6 80.0 AP-HCS-11-5 0.859 73.6 77.8 76.1 0.916 79.2 88.0 84.4 AP-HCS-11-6 0.847 66.1 83.4 77.2 0.942 86.1 69.8 88.3 AP-HCS-11-8 0.795 66.7 81.5 75.6 0.827 66.7 78.7 73.9 AP-HCS-11-10 0.870 69.4 83.3 77.8 0.899 80.6 87.0 84.4 Presenting Author: SHI QIU Corresponding Author: SHI QIU Affiliations: Wuhan university Objective: To investigate the expression of liver-intestine (LI)-cadherin in hepatocellular Carcinoma (HCC) by tissues microarray and explore its relationship with pathologic features of HCC patients. Methods: Seventy primary HCC resection samples with different indexing and five primary normal tissues samples were assessed by tissue microarray and immunohistochemistry based on the SP method.